Alverno Laboratories and Ibex Medical Analytics have collaborated to introduce an AI-powered cancer diagnostics platform. This platform, known as the Ibex Breast platform, is now in routine use within Alverno’s laboratory network in Illinois and Indiana. This launch is part of a phased rollout that includes AI solutions for various types of cancer, such as prostate, breast, and soon gastric cancer. The implementation of this platform aims to assist pathologists in identifying and grading areas suspicious of cancer, improving the accuracy and speed of diagnoses for patients.
Alverno Laboratories has integrated the Ibex platform with the Phillips IntelliSite Pathology Solution, enhancing the laboratory system’s diagnostic capabilities. With these advanced tools, pathologists can provide quicker and more accurate diagnoses, ultimately improving patient care by ensuring timely results for clinicians. The rollout of the Ibex Breast platform means that patients can access cutting-edge technology closer to home, eliminating the need to travel to larger cities for advanced cancer diagnostics.
The suite of solutions offered by Ibex supports pathologists in various tasks related to reviewing prostate, breast, and gastric biopsies. These solutions prioritize cases, aid in cancer detection using AI, optimize workflows, and enhance productivity in the laboratory setting. By implementing AI on a large scale, Alverno aims to improve pathologists’ efficiency, reduce costs, and enhance overall service levels across its network. Ibex’s technology has been widely deployed in pathology globally and has shown significant improvements in diagnostic accuracy and efficiency in clinical studies.
Joseph Mossel, CEO and co-founder of Ibex Medical Analytics, commended Alverno Laboratories for their commitment to innovation and patient care. The partnership between Ibex and Alverno highlights a shared dedication to providing high-quality diagnostics and improving outcomes for cancer patients. By expanding the use of the Ibex platform, Alverno continues to demonstrate its leadership in leveraging AI technology for cancer diagnosis.
Alverno Laboratories, based in Hammond, Indiana, offers pathology services and testing to communities in Illinois and Indiana. Through advanced technologies like digital pathology and AI, Alverno focuses on providing the best possible patient care. The collaboration with Ibex further demonstrates Alverno’s dedication to innovation and improving diagnostic capabilities for patients. Ibex Medical Analytics is a pioneer in AI-powered cancer diagnostics, with a mission to provide accurate and personalized cancer diagnoses for every patient. Their suite of solutions empowers physicians and supports pathologists in improving the accuracy and efficiency of cancer diagnosis.
The partnership between Alverno Laboratories and Ibex Medical Analytics represents a significant step forward in utilizing AI technology for cancer diagnostics. By integrating the Ibex Breast platform into routine practice, Alverno is enhancing its diagnostic capabilities and providing patients with access to cutting-edge technology closer to home. This collaboration underscores the importance of innovation in improving patient care and advancing the field of pathology.
